Staci Martin

3.1k total citations · 1 hit paper
23 papers, 686 citations indexed

About

Staci Martin is a scholar working on Neurology, Genetics and Oncology. According to data from OpenAlex, Staci Martin has authored 23 papers receiving a total of 686 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Neurology, 5 papers in Genetics and 5 papers in Oncology. Recurrent topics in Staci Martin's work include Neurofibromatosis and Schwannoma Cases (9 papers), Neuroblastoma Research and Treatments (8 papers) and CAR-T cell therapy research (3 papers). Staci Martin is often cited by papers focused on Neurofibromatosis and Schwannoma Cases (9 papers), Neuroblastoma Research and Treatments (8 papers) and CAR-T cell therapy research (3 papers). Staci Martin collaborates with scholars based in United States, Australia and Japan. Staci Martin's co-authors include Pamela L. Wolters, Cindy Delbrook, Bonnie Yates, Haneen Shalabi, Nirali N. Shah, Seth M. Steinberg, Brigitte C. Widemann, Eva Dombi, Daniel W. Lee and Terry J. Fry and has published in prestigious journals such as The Lancet, Circulation and Journal of Clinical Oncology.

In The Last Decade

Staci Martin

22 papers receiving 675 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL

2021 200 citations Nirali N. Shah, Daniel W. Lee et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Staci Martin United States	12	305	210	133	103	94	23	686
Gustavo Chagoya United States	17	107 0.4×	113 0.5×	143 1.1×	76 0.7×	137 1.5×	41	733
Jacob L. Goldberg United States	16	165 0.5×	258 1.2×	148 1.1×	82 0.8×	351 3.7×	85	967
Simon Hanft United States	15	78 0.3×	193 0.9×	63 0.5×	131 1.3×	43 0.5×	61	691
Samu Kurki Finland	17	230 0.8×	85 0.4×	109 0.8×	132 1.3×	161 1.7×	47	742
Markus J. Bookland United States	15	69 0.2×	185 0.9×	109 0.8×	88 0.9×	99 1.1×	49	685
Francisco Martínez‐Ricarte Spain	15	111 0.4×	214 1.0×	174 1.3×	168 1.6×	97 1.0×	33	778
Amol Mehta United States	15	88 0.3×	132 0.6×	102 0.8×	126 1.2×	81 0.9×	40	697
Leopold Arko United States	10	47 0.2×	150 0.7×	140 1.1×	100 1.0×	33 0.4×	12	758
Marie A. Neu Germany	10	211 0.7×	47 0.2×	111 0.8×	53 0.5×	21 0.2×	29	448
Steffen Fleck Germany	15	65 0.2×	261 1.2×	41 0.3×	61 0.6×	121 1.3×	44	798

Countries citing papers authored by Staci Martin

Since Specialization

Citations

This map shows the geographic impact of Staci Martin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Staci Martin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Staci Martin more than expected).

Fields of papers citing papers by Staci Martin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Staci Martin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Staci Martin. The network helps show where Staci Martin may publish in the future.

Co-authorship network of co-authors of Staci Martin

This figure shows the co-authorship network connecting the top 25 collaborators of Staci Martin. A scholar is included among the top collaborators of Staci Martin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Staci Martin. Staci Martin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Struemph, Kari, Staci Martin, Jason Levine, et al.. (2025). Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings. Journal of Patient-Reported Outcomes. 9(1). 46–46. 2 indexed citations

Chen, Alice P., Geraldine O’Sullivan Coyne, Pamela L. Wolters, et al.. (2025). Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study. The Lancet. 405(10496). 2217–2230. 1 indexed citations

Martin, Staci, et al.. (2024). Parent–child discrepancies in reports of child psychosocial functioning in neurofibromatosis type 1.. Journal of Family Psychology. 39(1). 99–106.

Gross, Andrea M., Eva Dombi, Pamela L. Wolters, et al.. (2023). Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. Neuro-Oncology. 25(10). 1883–1894. 44 indexed citations

Shalabi, Haneen, Staci Martin, Bonnie Yates, et al.. (2022). Neurotoxicity following CD19/CD28ζ CAR T-cells in children and young adults with B-cell malignancies. Neuro-Oncology. 24(9). 1584–1597. 20 indexed citations

Shah, Nirali N., Daniel W. Lee, Bonnie Yates, et al.. (2021). Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. Journal of Clinical Oncology. 39(15). 1650–1659. 200 indexed citations breakdown →

Conrey, Anna, Kamille A. West, Mary Jo Jackson, et al.. (2020). Computer Algorithm‐Based Hydroxyurea Dosing Facilitates Titration to Maximum Tolerated Dose in Sickle Cell Anemia. The Journal of Clinical Pharmacology. 61(1). 41–51. 1 indexed citations

Lurain, Kathryn, Thomas S. Uldrick, Ramya Ramaswami, et al.. (2020). Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate. Blood. 136(19). 2229–2232. 18 indexed citations

Coyne, Geraldine O’Sullivan, Andrea M. Gross, Eva Dombi, et al.. (2020). Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).. Journal of Clinical Oncology. 38(15_suppl). 3612–3612. 17 indexed citations

10.

Gross, Andrea M., Pamela L. Wolters, Andrea Baldwin, et al.. (2018). SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).. Journal of Clinical Oncology. 36(15_suppl). 10503–10503. 31 indexed citations

11.

Shalabi, Haneen, Pamela L. Wolters, Staci Martin, et al.. (2018). Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy. Journal of Immunotherapy. 41(7). 350–358. 58 indexed citations

12.

Bradford, Diana, Patricia Whitcomb, Eva Dombi, et al.. (2016). Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).. Journal of Clinical Oncology. 34(15_suppl). TPS2596–TPS2596. 1 indexed citations

13.

Shalabi, Haneen, Pamela L. Wolters, Staci Martin, et al.. (2016). A Prospective Evaluation of Neurocognitive Function and Neurologic Symptoms in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Undergoing Anti-CD22 Chimeric Antigen Receptor Therapy. Blood. 128(22). 1625–1625. 5 indexed citations

14.

Widemann, Brigitte C., Leigh Marcus, Michael J. Fisher, et al.. (2014). Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).. Journal of Clinical Oncology. 32(15_suppl). 10018–10018. 30 indexed citations

15.

Martin, Staci, Pamela L. Wolters, Mary Anne Toledo‐Tamula, et al.. (2013). Neurobehavioral Profiles in Individuals with Hyperimmunoglobulin E Syndrome (HIES) and Brain White Matter Hyperintensities. Journal of Clinical Immunology. 33(7). 1175–1184. 5 indexed citations

16.

Martin, Staci, Pamela L. Wolters, Andrea Gillespie, et al.. (2012). Social-emotional Functioning of Children and Adolescents With Neurofibromatosis Type 1 and Plexiform Neurofibromas: Relationships With Cognitive, Disease, and Environmental Variables. Journal of Pediatric Psychology. 37(7). 713–724. 57 indexed citations

17.

Kim, AeRang, Eva Dombi, Elizabeth Fox, et al.. (2012). Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. Pediatric Blood & Cancer. 60(3). 396–401. 55 indexed citations

18.

Wilson, Wyndham H., Pierluigi Porcu, David D. Hurd, et al.. (2005). Phase II study of dose-adjusted EPOCH-R in untreated de novo CD20+ diffuse large B-cell lymphoma (DLBCL)-CALGB 50103. Journal of Clinical Oncology. 23(16_suppl). 6530–6530. 4 indexed citations

19.

Martin, Staci, et al.. (2004). P0812 ELEVATED SERUM TRYSPSINOGEN AMONG CHILDHOOD ALLOGENEIC HEMATOPOETIC STEM CELL TRANSPLANT RECIPIENTS: AN INDICATOR OF POOR OUTCOME?. Journal of Pediatric Gastroenterology and Nutrition. 39(Supplement 1). S365–S366. 1 indexed citations

20.

Martin, Staci, Dennis E. Chenoweth, Robert L. Engler, David M. Roth, & John C. Longhurst. (1988). C5a decreases regional coronary blood flow and myocardial function in pigs: implications for a granulocyte mechanism.. Circulation Research. 63(2). 483–491. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact